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In 1967, it was reported that experimental inoculation of serum from a surgeon (G.B.) with acute
hepatitis into tamarins resulted in hepatitis. In 1995, two new members of the family Flaviviridae,
named GBV-A and GBV-B, were identified in tamarins that developed hepatitis following
inoculation with the 11th GB passage. Neither virus infects humans, and a number of GBV-A
variants were identified in wild New World monkeys that were captured. Subsequently, a related
human virus was identified [named GBV-C or hepatitis G virus (HGV)], and recently a more
distantly related virus (named GBV-D) was discovered in bats. Only GBV-B, a second species
within the genus Hepacivirus (type species hepatitis C virus), has been shown to cause hepatitis;
it causes acute hepatitis in experimentally infected tamarins. The other GB viruses have however
not been assigned to a genus within the family Flaviviridae. Based on phylogenetic relationships,
genome organization and pathogenic features of the GB viruses, we propose to classify GBV-A-
like viruses, GBV-C and GBV-D as members of a fourth genus in the family Flaviviridae, named
Pegivirus (pe, persistent; g, GB or G). We also propose renaming ‘GB’ viruses within the tentative
genus Pegivirus to reflect their host origin.
Introduction
The International Committee on Taxonomy of Viruses
(ICTV) provides guidelines for virus nomenclature and
classification based on orders (-virales), families (-viridae),
subfamilies (virinae), genera (-virus) and species (The
Universal Virus Database of the International Committee
on Taxonomy of Viruses; http://www.ncbi.nlm.nih.gov/
ICTVdb/index.htm). A species is a ‘polythetic class of
viruses that constitutes a replicating lineage and occupies a
particular ecological niche’. Several properties must be
present to differentiate individual species, including
differences in genome sequences, host range, cell and
tissue tropism, pathogenicity or cytopathology, physical
properties and antigenic properties. Within the family
Flaviviridae, the ICTV has classified hepatitis C virus
(HCV) as the type species within the genus Hepacivirus,
and GB virus B (GBV-B) has tentatively been assigned as a
second species within this genus (http://www.ncbi.nlm.nih.
gov/ICTVdb/index.htm). The related GBV-A and GBV-A-
like agents, and GBV-C (or hepatitis G virus; HGV) viruses
have also been assigned to the familyFlaviviridae,b u tn ottoa
genus (http://www.ncbi.nlm.nih.gov/ICTVdb/index.htm). A
related virus was recently discovered in Old World frugivo-
rous bats (Pteropus giganteus) and was termed GBV-D
(Epstein et al., 2010). In this review, we propose to assign
GBV-A, GBV-C/HGV and GBV-D as species within a new
genus, Pegivirus.I na d d i t i o n ,w es u g g e s tt h a tt h eG Bv i r u s e s
within this fourth genus of the family Flaviviridae berenamed
to reflect better their biological and pathogenic properties.
History
Following the discovery of hepatitis A virus (HAV) and
hepatitis B virus (HBV) in the 1960s and 1970s, it became Supplementary figures are available with the online version of this paper.
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chronic hepatitis frequently observed in recipients of blood
transfusions (Feinstone et al., 1975). Considerable research
was directed towards identifying the causative agent of
post-transfusion or ‘non-A, non-B’ hepatitis (Feinstone
et al., 1975; Feinstone & Purcell, 1978; Prince et al., 1974),
and well characterized human sera were shown to contain
an infectious agent that caused chronic, relapsing and mild
hepatitis in experimentally infected chimpanzees (Bradley
et al., 1983). Using a molecular cloning approach, Choo
et al. (1989) discovered an RNA virus in the serum and
tissues of a chimpanzee experimentally inoculated with
serum from an individual with chronic, non-A, non-B
hepatitis (Choo et al., 1989). This virus was shown to be
epidemiologically associated with non-A, non-B hepatitis
(Kuo et al., 1989), and chimpanzee studies confirmed that
the virus induced hepatitis (Bradley, 2000). The virus was
called hepatitis C virus (HCV) and it is classified as the
type species member of the genus Hepacivirus within the
family Flaviviridae (Choo et al., 1989).
In the process of studying non-A, non-B hepatitis,
Dienhardt and colleagues obtained serum from a surgeon
on day 3 of acute hepatitis (Deinhardt et al., 1967). This
serum apparently induced hepatitis when inoculated
into tamarins, a type of New World monkey (Saguinus
labiatus). Passage of serum obtained from the inoculated
animals at the time of hepatitis into new tamarins
produced similar hepatitis both in newly inoculated
tamarins and in other New World monkey species
(Deinhardt et al., 1967). Based on the initials of the
surgeon, the transmissible agent was called the ‘GB agent’,
and this agent was studied extensively as a putative cause of
non-A, non-B hepatitis (Deinhardt et al., 1967; Deinhardt
& Deinhardt, 1984; Gust & Feinstone, 1988). In 1995, a
group of investigators from Abbott Laboratories identified
two viruses in the serum and liver of tamarins inoculated
with the 11th tamarin passage of the GB agent (Simons
et al., 1995b). These viruses were named GB virus A and B
(GBV-A and GBV-B) due to the pedigree of the infectious
serum (Simons et al., 1995b). Using degenerate primers to
amplify related viral sequences in human serum samples, a
third virus was identified and termed GBV-C (Simons
et al., 1995a). Simultaneously, a research group at Genelabs
identified novel RNA virus sequences in the serum of
humans with non-A, non-B hepatitis, and called this virus
hepatitis G virus (HGV) (Linnen et al., 1996).
Subsequent analysis of the genome sequences of HGV and
GBV-C revealed that they were minor variants of the same
virus species, while GBV-A and GBV-B were distinct (Kim
& Fry, 1997; Leary et al., 1996b; Muerhoff et al., 1995). All
of the ‘GB’ viruses are distantly related to HCV (Linnen
et al., 1996; Simons et al., 1995a, b) and based on their
predicted genomestructure and nucleotide sequence relation-
ships, the three ‘GB’ viruses were classified as members of the
family Flaviviridae (http://www.ncbi.nlm.nih.gov/ICTVdb/
index.htm). Phylogenetic analysis of conserved regions of
translated sequences from the helicase and polymerase
domains revealed a closer relationship of HCV to GBV-B,
while GBV-A and GBV-C/HGV form a separate cluster
(Muerhoff et al., 1995; Simons et al.,1 9 9 5 a ) .G B V - B
represented the true GB-agent. Although it apparently did
not originate from the surgeon GB and does not infect
humans or chimpanzees, it caused acute hepatitis in
experimentally infected tamarins, including animals trans-
fected intrahepatically with RNA transcripts of recombinant
GBV-B (Bukh et al., 1999; Lanford et al., 2003; Martin et al.,
2003; Nam et al., 2004). In contrast, GBV-A represented
indigenous tamarin viruses not associated with hepatitis
(Simons et al., 1995b), and a number of GBV-A-like agents
were subsequently identified from New World monkeys
(Bukh & Apgar, 1997; Leary et al., 1996a; Simons et al.,
1995b). GBV-C was found to be a frequent human virus that
was not associated with viral hepatitis (Alter, 1997; Alter etal.,
1997a; Simons et al., 1995a).
Recently, using unbiased, high-throughput pyrosequencing
methods, a virus more distantly related to GBV-A, GBV-B
and GBV-C/HGV was identified in serum samples
obtained from Old World frugivorous bats (P. giganteus)
in Bangladesh (Epstein et al., 2010). Two full-length
sequences were generated that share approximately 50%
amino acid sequence identity with GBV-A and GBV-C/
HGV (Epstein et al., 2010). This novel virus was named
GBV-D.
For three reasons, we suggest that the current nomencla-
ture assigned to the ‘GB’ viruses should be changed. Firstly,
there is no evidence that the surgeon (GB) for whom these
viruses are named was infected with GBV-A, GBV-B, GBV-
C/HGV or GBV-D. Secondly, infections and susceptibility
to GBV-A and GBV-B have subsequently been shown to be
restricted to New World primates, and to date, GBV-D
appears to be restricted to bats. Thus, it is highly unlikely
that they originated from the surgeon ‘GB’. Finally, GBV-
C/HGV does not cause hepatitis in humans. In this
manuscript, we review the clinical and virological aspects
of these viruses and re-examine their genetic relationships.
Based on these observations we propose a change in
nomenclature of GBV-A, GBV-C/HGV and GBV-D to
better and more clearly describe these viruses. Since GBV-B
represents what for years has been referred to as the GB-
agent, and since the natural host(s) of this virus remain
unknown, we at present propose to remove the ‘B’
designation and call the virus ‘GBV’, as it will be the only
GB virus under the proposed classification system.
Virology
Epidemiology and transmission
HCV and GBV-C/HGV infections occur worldwide
(reviewed by Lauer & Walker, 2001; Stapleton, 2003). It
has been estimated that perhaps as many as 3% of the
world’s population has been infected with HCV (The
Global Burden of Disease Working Group, 2004).
Frequencies of GBV-C/HGV infection are difficult to
determine, but prevalence studies suggest that 1–4% of
J. T. Stapleton and others
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viraemic at the time of blood donation, and another 5–
13% have anti-E2 antibodies, indicating prior infection
(Blair et al., 1998; Gutierrez et al., 1997; Pilot-Matias et al.,
1996a; Tacke et al., 1997). In developing countries, blood
donor viraemia prevalence is higher, approaching 20% in
some regions of the world (reviewed by Mohr & Stapleton,
2009; Polgreen et al., 2003).
Among people with blood-borne or sexually transmitted
infections, GBV-C/HGV is more prevalent (Scallan et al.,
1998), and in one study of human immunodeficiency virus
(HIV)-infected homosexual men, 39.6% had viraemia and
46% had E2 antibody detected for a total exposure rate of
85.6% (Williams et al., 2004). These data, in combination
with the blood donor studies, suggest that at least one
quarter of the world’s population has been infected with
GBV-C/HGV. In contrast, sexual transmission of HCV is
inefficient, and most transmission occurs through exposure
to blood or from mother to child during birth (Lauer &
Walker, 2001).
Of the non-human GB viruses, GBV-A and GBV-B can be
experimentally transmitted to different species of New
World monkeys via the blood-borne route. It is not clear if
sexual, vertical or other modes of transmission occur for
these two viruses. Following identification, GBV-D RNA
was detected using real-time PCR methods in 5 of 98 (5%)
P. giganteus (bat) serum samples in a population of wild
bats in Bangladesh. No further epidemiological studies
have been reported. Although there are no data to indicate
the mode of GBV-D transmission, viral RNA was identified
in the saliva in one of the five bats with viraemia,
suggesting horizontal and potentially zoonotic transmis-
sion, and none of the viraemic bats had GBV-D RNA
detected in urine (Epstein et al., 2010).
Pathogenesis and cellular tropism
HCV and GBV-B viruses are primarily detected in the liver
of naturally infected humans and experimentally infected
New World monkeys, respectively, although viral genomes
can be found in peripheral blood mononuclear cells
(PBMCs) in some infected hosts (Beames et al., 2000;
Bright et al., 2004; Bukh et al., 2001a; Fong et al., 1991; Ishii
et al., 2007; Jacob et al., 2004; Laskus et al., 1997b; Simons
et al., 1995b). GBV-B has not been identified in New
World primates except in experimentally infected animals.
High levels of virus are present in the blood, typically
between 1–10 million genome equivalents ml
21 for HCV
and 102100 million genome equivalents ml
21 for GBV-B.
GBV-A and GBV-A-like agents, and GBV-C/HGV viruses
are present in low or non-detectable levels in the liver of
infected hosts, and the viruses are more readily detected in
circulating lymphocytes, suggesting that GBV-A and GBV-
C could be lymphotropic, and not hepatotropic (Kobayashi
et al., 1999; Laskus et al., 1997a, 1998; Pessoa et al., 1998;
Radkowski et al., 1999, 2000; Simons et al., 2000; Tucker
et al., 2000). Although replication of HCV and GBV-C/
HGV in hepatocyte and lymphocyte cell culture has been
described, HCV and GBV-B replication is optimal in
cultured cells of hepatocyte origin (Beames et al., 2000;
Lanford et al., 1994; Lindenbach et al., 2005a; Wakita et al.,
2005; Zhong et al., 2005). In contrast, GBV-C/HGV
replication is most frequently accomplished in PBMCs,
including the CD4 and CD8 T lymphocyte subsets, and B
lymphocytes (Fogeda et al., 1999; George et al., 2003, 2006;
Xiang et al., 2000). Cell culture replication of GBV-A or
GBV-D has not been described. Serum concentrations of
GBV-D RNA ranged from 350 to 70000 genome copies
ml
21 (Epstein et al., 2010), but bat liver, PBMCs or other
cell types have not been assessed for evidence of viral
replication.
Viral RNA transcripts and/or serum are infectious in
animal models for HCV and GBV-B (Beames et al., 2001;
Bukh et al., 1999, 2001a; Jacob et al., 2004; Kolykhalov
et al., 1997; Lanford et al., 2001, 2003; Martin et al., 2003;
Nam et al., 2004; Sbardellati et al., 2001; Yanagi et al.,
1997), and for cell culture models for HCV, GBV-B and
GBV-C/HGV (Beames et al., 2000; Lindenbach et al.,
2005a, 2006; Wakita et al., 2005; Xiang et al., 2000; Zhong
et al., 2005). Consistent with the tropism of these viruses,
both HCV and GBV-B are associated with hepatitis (Bukh
et al., 2001a; Hoofnagle, 1997; Simons et al., 1995b), but
GBV-A and GBV-C/HGV are not associated with hepatitis
in clinical and experimental studies (Alter et al., 1997a,
b; Schlauder et al., 1995; Simons et al., 1995b). No
experimental transmission studies of GBV-D have been
reported; however, no difference in liver enzyme values in
serum was identified in bats with GBV-D viraemia (Epstein
et al., 2010).
Persistence and humoral immunity
HCV and GBV-A infection frequently leads to persistent
viraemia, with approximately 80% of HCV infections and
all GBV-A infections studied longitudinally, resulting in
life-long infection (Hoofnagle, 1997; Lauer & Walker, 2001;
Simons et al., 1995b). Neutralizing antibodies are detect-
able against HCV in at least 95% of persistently viraemic
individuals (Lauer & Walker, 2001; Owsianka et al., 2008).
Their role in chronic HCV hepatitis remains poorly
defined. Although antibodies to GBV-A were not identified
during acute or chronic infection, this may relate to the
paucity of reagents available for GBV-A (Simons et al.,
1995b).
GBV-B is usually cleared by the host 1–6 months after
experimental infection of tamarins (Bukh et al., 2001a;
Jacob et al., 2004; Simons et al., 1995b), and no persistent
infection has been observed in animals infected with virus
particles. However, infection was present at the time of
sacrifice in two animals (90 weeks and 2 years, respec-
tively) that were injected intrahepatically with full-length,
synthetically transcribed GBV-B RNA (Martin et al., 2003;
Nam et al., 2004). Further passage of GBV-B derived from
The GB viruses
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self-limited infection, suggesting that the observed persis-
tence was related to host genetic factors rather than a
property of the specific GBV-B isolate (Jacob et al., 2004).
The majority of immune competent individuals infected
with GBV-C/HGV clear viraemia within 2 years of
infection (Berg et al., 1999; Tanaka et al., 1998). Unlike
HCV, which elicits antibodies to several viral proteins
during viraemia that usually persist throughout infection
(Baumert et al., 2000), GBV-C/HGV antibodies are not
generally detected during viraemia, although some studies
have reported the detection of anti-GBV-C/HGV peptide
reactivity (Fernandez-Vidal et al., 2007; Gomara et al.,
2010; Pilot-Matias et al., 1996b; Schwarze-Zander et al.,
2006; Tan et al., 1999; Van der Bij et al., 2005; Xiang
et al., 1998). Following clearance of GBV-C/HGV viraemia,
most individuals develop conformation-dependent anti-
bodies to the envelope glycoprotein E2, and thus E2
antibody serves as a marker of prior infection (Barnes et al.,
2007; Gutierrez et al., 1997; McLinden et al., 2006;
Nakatsuji et al., 1992; Pilot-Matias et al., 1996a; Tacke
et al., 1997; Tanaka et al., 1998). Detection of anti-GBV-C/
HGV antibodies occurs coincidently with clearance of
viraemia and appears to be restricted to E2, suggesting that
this E2 antigenic site is immunodominant in humans
(McLinden et al., 2006). In addition, HCV and GBV-C/
HGV particles contain high concentrations of lipids, and as
a result have very low buoyant densities (,1.10 g cm
23)
(Agnello et al., 1999; Hijikata et al., 1993; Melvin et al.,
1998; Monazahian et al., 1999, 2000; Thomssen et al., 1992,
1993; Wunschmann et al., 2000, 2006; Xiang et al., 1998). It
is possible that these virus-associated lipids mask the HCV
and GBV-C/HGV neutralization epitopes and contribute
to viral persistence. However, this does not explain the
failure of humans to develop antibodies to non-structural
(NS) proteins in GBV-C/HGV infections, and suggests that
the virus interacts with the humoral immune response.
By comparing the number of healthy blood donors with
either GBV-C/HGV viraemia or E2 antibody, it appears
that approximately 80% of healthy people spontaneously
clear viraemia (Gutierrez et al., 1997; Nakatsuji et al., 1992;
Pilot-Matias et al., 1996a; Tacke et al., 1997; Tanaka et al.,
1998). Among HIV-infected subjects, the frequency of
GBV-C/HGV clearance appears to be reduced, as the
prevalence of viraemia is increased, while E2 antibody
prevalence is generally the same or higher than in HIV-
uninfected individuals (Dorrucci et al., 1995; Heringlake
et al., 1998; Williams et al., 2004). Thus, the proportion of
individuals with viraemia compared with those with E2
antibody is increased. GBV-C/HGV viraemia has been
documented to persist for decades (Alter, 1997; Barnes
et al., 2007), and by analogy with other viruses such as
HBV, it is possible that higher frequencies of persistence
may occur in individuals exposed very early in life. GBV-C/
HGV infection of chimpanzees (GBV-Ccpz or GBV-Ctro)
may also persist in infected animals throughout 19 years
of follow-up. However, like GBV-C/HGV in humans, it
appears that the majority of infections in chimpanzees are
self limited (Mohr et al., 2010).
Although HCV antibodies frequently persist in those who
clear viraemia, HCV antibody titres wane over time, and
longitudinal studies have revealed a substantial proportion
of HCV-infected individuals without residual serological
markers of infection (Takaki et al., 2000). Antibodies may
prevent challenge with autologous virus (Farci et al., 1994;
Tabor et al., 1980), but they do not prevent superinfection
(Farci et al., 1992a). Nevertheless, neutralizing antibodies
directed against conserved HCV epitopes have been
identified, and are actively being studied for immunother-
apy or as potential vaccine immunogens (Keck et al., 2004).
To date, no antibodies to GBV-A have been detected,
suggesting that GBV-A also somehow evades host recog-
nition. However, there is a paucity of studies and reagents
available for GBV-A, so humoral immunity in GBV-A
cannot be conclusively described (Schaluder et al., 1995).
In contrast, GBV-B antibodies are present following
viraemia clearance and were thought to prevent or atten-
uate experimental infection in marmosets (Schaluder et al.,
1995). However, although a subsequent study found
evidence of protection following GBV-B infection, this
did not appear to involve humoral immunity (Bukh et al.,
2008). Antibodies to GBV-B, HCV and GBV-C/HGV
frequently decline following clearance of viraemia, some-
times below the limit of detection. Thus, antibody detec-
tion may underestimate the prevalence of prior infection.
Information regarding GBV-D persistence or serological
responses has not yet been described.
Host range
Despite the similarities in genome organization and
existence of homologous proteins, specific host range
differences exist among HCV, GBV-A, GBV-B, GBV-C/
HGV and GBV-D. HCV and GBV-C/HGV infect Old
World primates, while GBV-A and GBV-B infect New
World primates. Specifically, natural HCV infection is
limited to humans, although experimental infection of
chimpanzees is well documented (Farci et al., 1992b;
Shimizu et al., 1990; Tabor et al., 1979). Natural infection
of humans and chimpanzees with GBV-C/HGV is well
documented (Adams et al., 1998; Birkenmeyer et al., 1998;
Linnen et al., 1996; Simons et al., 1995a), and sequences of
isolates obtained from chimpanzee (GBV-Ccpz or GBV-
Ctro) form a separate phylogenetic group from human
GBV-C/HGV (Adams et al., 1998; Birkenmeyer et al.,
1998). The host range for experimental infection with HCV
and human GBV-C/HGV infection appears to be restricted
to humans and chimpanzees (Bukh et al., 1998, 1999, 2001b,
2008),although small studies suggestthat HCV and GBV-C/
HGV may infect some Old World monkeys (Macaca)
(Cheng et al., 2000; Krawczynski, 1997; Majerowicz et al.,
2004; Ren et al., 2005; Vitral et al., 1997). This is
controversial, as neither HCV nor GBV-C/HGV infection of
macaques was reproduced by other laboratories (Bukh et al.,
J. T. Stapleton and others
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Thomas, Jian-Qiu Han, Binhua Ling, Jinhua Xiang and Jack
Stapleton). Thus, it is not clear if organisms other than
humans and chimpanzees are susceptible to HCV and GBV-
C/HGV infection.
In contrast, the natural hosts of GBV-A and GBV-A-like
variants include at least six species of New World monkeys
including Saguinus species (Saguinus labiatus, Saguinus
mystax, Saguinus nigricollis and Saguinus oedipus),
Callithrix species (Callithrix jacchus) and Aotus species
(Aotus trivirgatus) (Bukh & Apgar, 1997; Leary et al., 1996a;
Muerhoff et al., 1995; Simons et al., 1995b). The 59 non-
translated region (NTR) and NS3 helicase sequences of
GBV-A isolates from different host species were found to
segregate into distinct groups, suggesting co-speciation of
these viruses with their natural hosts (Bukh & Apgar, 1997;
Leary et al., 1996a; Muerhoff et al., 1995; Simons et al.,
1995b). In contrast, no natural host for GBV-B has been
identified. Experimental GBV-B infection of tamarins and
aotus monkeys have been documented, but experimental
inoculation into chimpanzees did not provide evidence of
viral replication (Bukh et al., 2001a). Identification of the
natural host of GBV-B may be complicated by the short
duration of viraemia and the lack of a reliable serological
method to detect prior infection (Pilot-Matias et al., 1996b;
Schaluder et al., 1995). Alternatively, tamarins may not be
the natural host of GBV-B, and the virus may indeed be
capable of establishing persistent infections in an altern-
ative, natural host. GBV-D has only been reported in one
bat species (Epstein et al., 2010). A summary of the host
range, tropism and pathogenesis is presented in Table 1.
Genome organization
Like other members of the family Flaviviridae, HCV, GBV-
A, GBV-B, GBV-C/HGV and GBV-D have a positive-sense,
ssRNA genome that contains a single long ORF encoding a
multifunctional polyprotein (Fig. 1) (Birkenmeyer et al.,
1998; Choo et al., 1991; Kim & Fry, 1997; Leary et al.,
1996b; Muerhoff et al., 1995). The 59 NTR contains an
internal ribosomal entry site (IRES) element that directs
translation of the polyprotein directly from viral genomic
RNA (Simons et al., 1996; Yoo et al., 1992), and translation
and release of the viral RNA-dependent RNA polymerase
(RdRp) initiates RNA replication (reviewed by Major &
Feinstone, 1997; Mohr & Stapleton, 2009; Moradpour
et al., 2007; Robertson, 2001). The viral structural proteins
are processed from the amino-terminal portion of the
polyprotein by cellular signal peptidases or signal peptide
peptidase, while the NS proteins are processed by two viral
encoded proteases. An NS2–NS3 autoprotease catalyses the
cleavage of NS2–NS3 for HCV, and based on the
conservation of two essential amino acids for HCV NS2
function (His-952 and Cys-993), NS2-mediated cleavage of
NS2–NS3 is thought to occur in GBV-A, GBV-B, GBV-C/
HGV and GBV-D viruses as well. The remaining NS
proteins are cleaved by the NS3 protease with its co-factor
NS4A in HCV, GBV-B, GBV-C/HGV and presumably
GBV-A and GBV-D (reviewed by Epstein et al., 2010;
Major & Feinstone, 1997; Mohr & Stapleton, 2009;
Moradpour et al., 2007; Robertson, 2001). Like NS2, NS3
amino acids essential for the processing of HCV NS
proteins (His-1083, Asp-1107 and Ser-1165) are present in
all four GB viruses and HCV. Their NS3 proteases are
classified as chymotrypsin-like serine proteases (reviewed
by Major & Feinstone, 1997; Mohr & Stapleton, 2009;
Moradpour et al., 2007; Robertson, 2001).
Although HCV and the four GB viruses have somewhat
similar genome organization and predicted protein struc-
ture, there are distinct differences. All of the GB viruses
studied have an IRES element in the 59 NTR, although their
structures differ, with GBV-B having a type 3 IRES, like
HCV, while the IRES element in GBV-A and GBV-C/HGV
conform better with type 4 IRES elements (Kieft, 2008).
However, others state that the GBV-A and GBV-C/HGV
IRES do not conform to any recognized IRES class
(Bakhshesh et al., 2008). IRES activity has not been
examined in GBV-D. Direct comparative data do not exist
Table 1. Comparison of tropism, host range and pathogenesis of GB viruses and Hepaciviruses
IDA, Insufficient data available; NWP, New World primates.
Virus Proposal* Tropism Host range Pathogenesis
Pegivirus
GBV-C HPgV LymphocytesD Humans, chimpanzee None identified
GBV-Ccpz SPgVcpz IDA Chimpanzee None identified
GBV-A SPgV LymphocytesD NWP None identified
GBV-D BPgV IDA Bats IDA
Hepacivirus
HCV HCV Hepatoctyes Humans, chimpanzee Hepatitis
GBV-B GBV Hepatocytes NWP Hepatitis
*Genus (italics) and virus nomenclature proposed in this review.
DData support lymphotropism, but other sites of replication are possible.
The GB viruses
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for GB viruses. The 59 NTRs of HCV isolates are
approximately 340 nt long, whereas the 59 NTR of GBV-
B is 445 nt, and the contained IRES directs the translation
of a core protein. In contrast, the 59 NTRs for GBV-A and
GBV-C/HGV are predicted to be longer based on in vitro
translation studies that demonstrated that the AUG at
position 556 of GBV-C/HGV was the codon that initiated
translation (Simons et al., 1996). Sequence numbering is
based on the infectious clone isolate (Xiang et al., 2000)
(GenBank accession no. AF121950). Thus, GBV-A and
some GBV-C/HGV isolates do not appear to encode a core
protein (Kim & Fry, 1997; Leary et al., 1996b; Xiang et al.,
1998). A signal peptidase cleavage site is predicted to occur
17 or 21 aa downstream of the putative initiation codon in
GBV-C/HGV (Mohr & Stapleton, 2009), although it is
doubtful that this small peptide could serve as the core
(nucleocapsid) protein. Biophysical characterization of
GBV-C/HGV particles, however, found that they appear
to have a nucleocapsid (Xiang et al., 1998). Although there
is limited experimental evidence, several potential hypo-
theses have been put forward to explain the potential
source of the nucleocapsid protein. These include the
possibility that the capsid forms from the very small
cleaved peptide at the N terminus of the polyprotein
(Xiang et al., 1998), or that a longer core protein is
translated off an alternative reading frame on the genomic
or negative strands of the GBV-C/HGV genome.
Alternatively, the hypothesis that the virus utilizes a
cellular protein to serve as the nucleocapsid protein has
been raised (Theodore & Lemon, 1997).
It is unclear which AUG codon initiates translation in
GBV-D. Like GBV-C, there are multiple potential initiation
codons in-frame with the GBV-D coding sequence.
Specifically, there are five AUG codons between the 59
end of the GBV-D genome and nt 744 that are in-frame
with the long ORF (GenBank accession nos GU566734 and
GU566735). Of note, the predicted amino acid sequence of
GBV-D starting at nt 744 is MAVLLLLSTGLAEG. The
GBV-C predicted amino acid sequence starting at the AUG
shown to initiate translation in vitro (Simons et al., 1996)
is MAVLLLLLVVEAGA, thus sharing complete identity
with the first seven amino acids of GBV-D. GBV-A and
Fig. 1. Genome organization of the GB viruses and HCV. All four viruses contain a positive-polarity ssRNA genome with a 59
NTR and 39 NTR. The genome encodes a polyprotein that is co- and post-translationally cleaved into individual viral proteins.
The structural proteins include core (C) and envelope glycoproteins (E1 and E2), and the NS proteins include NS2–NS5B. The
presence of a genomic coding region for a C protein has not been identified for GBV-A or GBV-C. Structural proteins are
cleaved by cellular signal peptidases (open arrows), and the NS2–NS3 cleavage is accomplished by the NS2–NS3
autoprotease (shaded arrows). The remaining NS proteins are cleaved by the NS3–NS4A protease complex (solid block
arrows). The predicted genome organization of GBV-D was based on a polyprotein starting nt 18 of GU566735. *, The
predicted sizes of the proteins analogous to the HCV p7 are 21 kDa for GBV-A and 6 kDa for GBV-C. The existence of a GBV-
D p7-like protein is not clear from sequence analysis. **, The size of the protein corresponding to the HCV p7 in GBV-B is
13 kDa; this protein could be cleaved into p7 and p6 proteins, of which the p7 protein, but not the p6 protein is critical for
viability in vivo. Proposed names for GB viruses are in parentheses.
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tial polyprotein initiation region as well. The GBV-Atri
sequence is MEVLLVLLLKTALAGA, GBV-Alab sequence is
MELLLLLVLLAPAGA and the GBV-A sequence is MASL-
WFFVLLLPLGGGG. Until the GBV-D translation initiation
codon is identified, it will be difficult to assign precise
predicted structural protein sizes. Analysis of the GBV-D
polyprotein starting at the first AUG demonstrates four
predicted signal peptidase sites in the polyprotein using
the AUG at nt 57 as the translation start (Epstein et al.,
2010). These are located at amino acid numbers 57–58, 247–
248, 584–585 and 826–827. A 57 aa residue long protein
(6 kDa) that is highly basic (pI 12) was proposed as the
nucleocapsid or core protein for GBV-D (Epstein et al.,
2010), the genome would then have to have an extremely
short 59 NTR (57 nt), unless the true 59 end sequence was
not identified. Further experimental work is required to
determine the genome organization of this newly described
virus.
Additional differences between the various GB viruses and
HCV occur in the extent of predicted glycosylation of the
two envelope proteins (E1 and E2). HCV is the most
heavily glycosylated, followed by GBV-B, GBV-A and
GBV-C/HGV (reviewed by Mohr & Stapleton, 2009). GBV-
D is predicted to have 13 glycosylation sites, which would
place it similar to GBV-B and HCV. There may be an
additional glycoprotein between E2 and NS2 of GBV-D.
This region of the polyprotein was called the ‘X’ protein by
the group that discovered the virus (Epstein et al., 2010).
HCV and GBV-B has a p7 and a p13 protein, respectively,
between E2 and NS2 that is essential for their viability
(Sakai et al., 2003; Takikawa et al., 2006). The HCV p7
protein is believed to be important for virus assembly and
release (Sakai et al., 2003; Lindenbach & Rice, 2005b). It is
not known whether GBV-A and GBV-C have a corres-
ponding protein. The 39 NTR of HCV and GBV-B contain
poly-U tracts, while GBV-A, GBV-C and GBV-D do not
(Birkenmeyer et al., 1998; Kim & Fry, 1997; Leary et al.,
1996b; Muerhoff et al., 1995). In addition, HCV and GBV-
B have highly structured 39 terminal sequences
(Lindenbach & Rice, 2005b). Finally, a number of
differences occur in the predicted size of the NS proteins;
however, with the exception of HCV and GBV-B, the
experimental evidence to demonstrate differences is lack-
ing. A summary of genome organizational features that
differ among the GB viruses and HCV is shown in Table 2.
Phylogentic relationships
Unweighted pair group method analysis (UPGMA) and
neighbour-joining (NJ) analyses are common methods
used to generate a single tree, which can be a starting point
for evolutionary analysis. Alternatively, a ‘character-based’
approach evaluates the relatedness of sequences based on a
subset of positions called ‘informative sites’. Weighted and
unweighted Parsimony methods and maximum-likelihood
are frequently used approaches that generate multiple trees
(cladograms), which can be evaluated for accuracy (Smith
et al., 2000). Repeat analyses of a group of sequences in
which a proportion of sites are randomly resampled and
used for phylogenetic analysis is called ‘bootstrapping’,
which estimates the frequency that a particular branch
(node) in the tree occurs for each sample. Support for a
grouping is considered present when a branch occurs in
more than 70% of 1000 replicates (Smith et al., 2000).
Analysis of conserved amino acid sequence motifs involved
in the enzymic function of HCV, and GBV-A, GBV-B,
GBV-C and GBV-D may elucidate their evolutionary
relationship to each other and other members of the
family Flaviviridae (Bukh & Apgar, 1997; Muerhoff et al.,
1995; Robertson, 2001; Sathar et al., 1999; Schlauder et al.,
1995; Smith et al., 2000). The helicase region within NS3
share amino acid sequence identity in six domains
(Supplementary Fig. S1, available in JGV Online), while
the RdRp protein contains eight conserved motifs
(Supplementary Fig. S2, available in JGV Online) (Adams
Table 2. Genome features of GB viruses and HCV
IRES, Internal ribosome entry site; NC, not classified. GBV-A and GBV-C/HGV share a somewhat longer 59 NTR and lack an apparent coding
region for a core protein, 39 NTR polyuridine sequences, and have a lesser amount of predicted envelope protein glycosylation. There are
insufficient data available to predict 59 NTR or core protein length at this time for GBV-D.
Virus Proposal* 5§ NTR Core protein Envelope protein
glycosylation
3§ NTR
GBV-A SPgV ~540 nt, IRES NC Not identified 3–7 No poly U
GBV-B GBV 445 nt, type 3 IRES 156 aa 10 Poly U
GBV-C HPgV 555 nt, NC Not identified 4D No poly U
GBV-Ccpz SPgVcpz ~ 550 nt, NC Not identified 3 No poly U
GBV-D BPgV Not identified Not identified 13D No poly U
HCV HCV ~340 nt, type 3 IRES 191 aa 14–16 Poly U-UC
*Nomenclature proposed in this review.
DPredicted.
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Gorbalenya & Koonin, 1989; Koonin, 1991; Koonin &
Dolja, 1993; Leary et al., 1996b; Linnen et al., 1996;
Muerhoff et al., 1995; Robertson, 2001; Simons et al.,
1995a; Smith et al., 2000). Alignments were performed by
hand, based on the alignments of Koonin et al. that were
used as a guide (Gorbalenya & Koonin, 1989; Koonin &
Dolja, 1993). Helicase sequences of members of the family
Flaviviridae fall within the helicase supergroup II, and their
RdRp sequences place them into the RdRp supergroup II.
UPGMA analysis of the six conserved helicase domains and
eight conserved RdRp motifs with their intervening
sequences of HCV, GBV-A, GBV-B, GBV-C and GBV-D
confirm that these viruses are related to the Pestivirus and
Flavivirus genera within the family Flaviviridae (Fig. 2).
GBV-A, GBV-C and GBV-D group together, and GBV-B
groups with HCV, consistent with the proposed assign-
ment as a second species within the genus Hepacivirus.N J
analysis of the helicase and RdRp sequences including the
intervening sequences between the conserved domains
identified similar genetic relationships (Fig. 3), as did tree
methods using CLUSTAL alignments of these sequences (data
not shown). Despite the agreement between trees con-
structed by the two methods used here, final assignment
into specific genera should also consider genome structure,
tissue tropism and pathogenesis.
Fig. 2. Helicase and RdRp phylogenetic trees
of selected members of the family Flaviviridae.
UPGMA phylogenetic trees of helicase and
RdRp were generated using the alignments
shown in Supplementary Figs S1 and S2,
respectively. GenBank numbers for all isolates
used in these analyses are provided in the
legend for Supplementary Fig. S1. The node
numbers represent the bootstrap values
(expressed as a percentage of all trees)
obtained from 2000 replicates. The tree was
rooted by using the midpoint of the longest
branch. A distance scale in amino acid
substitutions per position is shown.
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We propose that GBV-A, GBV-A-like agents, GBV-C/HGV
and GBV-D should be classified together within a new
genus (Pegivirus) within the family Flaviviridae. This is
based on their phylogenetic relationships, genome struc-
ture, ability to persist in vivo and apparent lack of
pathogenicity. This designation indicates that these viruses
cause persistent infection (Pe), and provides historical
recognition of the relationship with the ‘GB’ agents and
hepatitis G virus (g). We propose to rename GBV-A as
simian pegivirus (SPgV). This indicates the primate host
range (S) and through the genus designation provides
historical reference to their relationship to the ‘GB’ serum
inoculation (Pg). The host species for different GBV-A
variants will be identified by subscript suffixes. For
example, SPgV will include SPgVmys, SPgVtri, SPgVlab and
SPgVjac. We propose to rename GBV-C/HGV as human
pegivirus (HPgV) for similar reasons, and genotypes will be
identified by subscript suffixes. The chimpanzee GBV-C
variants would be called SPgVcpz to reflect its simian host.
The recently reported GBV-D virus found in fruit bats
would be described as Bat PgV (BPgV). Should related
BPgV isolates be identified in different species, the host
species of the current bat isolate will be designated by the
subscript suffix (pgi) for the current virus identified in the
species P. giganteus, and the new related viruses will be
identified by their host species. This nomenclature avoids
the suggestion that these viruses either cause hepatitis or
were derived from the surgeon ‘GB’.
We support the proposal to classify GBV-B as a second
species within the genus Hepacivirus, as this virus causes
hepatitis in experimentally infected tamarins, thus it was
the true GB-agent (Thiel et al., 2005). Although the
surgeon GB would not have been infected with this virus, it
is the agent responsible for the hepatitis observed in
tamarins used in serial passage studies. Since, under the
proposed nomenclature, there will not be any other ‘GB’
viruses, we propose to rename GBV-B as GB virus (GBV).
Although the ‘GB’ serum was associated with hepatitis
following inoculation into tamarins, the specific agent(s)
responsible for the hepatitis remain unknown and the
reported hepatitis may simply relate to the relatively
common finding of non-specific enzyme elevation. A
summary of the classification proposal is shown in Fig. 4.
Our proposal to rename GBV-A, GBV-C/HGV and GBV-D
viruses and to classify them within a new genus (Pegivirus)
will be submitted to the International Committee on
Fig. 3. Helicase and RdRp phylogenetic trees of selected members of the family Flaviviridae. NJ analyses were performed on
the conserved motifs aligned as shown in Supplementary Figs S1 and S2, and their intervening sequences. A distance scale in
amino acid substitutions per position is shown.
The GB viruses
http://vir.sgmjournals.org 241Taxonomy of Viruses (ICTV) for consideration. We believe
that this classification clarifies that these viruses share
several biological features including similar phylogeny and
genome structures, the ability to cause persistent infection
in their respective hosts, and finally, that they do not cause
hepatitis. If closely related viruses are identified in different
host species, we recommend that they be designated by the
host genus for the first initial, followed by PgV. These new
designations will better clarify the relationships between
the ‘GB’ agents and resolve confusion regarding their
relationship to the surgeon ‘GB’.
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